ReviewMycopathologia2022
Characteristics and Prognosis of Talaromyces marneffei Infection in HIV-positive Children in Southern China.
Review in Mycopathologia, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.
- Characteristics of Endemic Mycoses Talaromyces marneffei Infection Associated with Inborn Errors of Immunity.Journal of clinical immunology · 2024Pooled it
- Talaromyces marneffei infection of central nervous system in an immunocompetent child in a nonendemic area: a case report and literature review.BMC pediatrics · 2026Review
- Clinical Features and Diagnostic Challenges ofInfection and drug resistance · 2026Article
- The Role of Talaromyces Marneffei Binding To CD86 in the CD86-CTLA4 Regulatory Pathway.Current microbiology · 2025Article
- A combined model based on lung CT imaging and clinical characteristics for the diagnosis of AIDS with infection of Talaromyces marneffei.BMC infectious diseases · 2025Article
- Clinical manifestations in patients with anti-IFN-γ autoantibodies syndrome and Talaromyces marneffei infection: a prospective cohort study.BMC infectious diseases · 2025Article
- Case Report:Frontiers in pediatrics · 2025Article
- Human inborn errors of immunity underlyingFrontiers in immunology · 2025Article
- Excavation of Biomarker Candidates for the Diagnosis ofACS omega · 2024Article
- Disseminated CombinedInfection and drug resistance · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 4 institutions in 3 countries.
Funding
Abstract
Knowledge about the clinical characteristics and prognostic factors of Talaromyces marneffei infection in children is limited, especially in HIV-positive children. We performed a retrospective study of all HIV-positive pediatric inpatients with T. marneffei infection in a tertiary hospital in Southern China between 2014 and 2019 and analyzed the related risk factors of poor prognosis using logistic regression. Overall, 28 cases were enrolled and the prevalence of talaromycosis in AIDS children was 15.3% (28/183). The median age of the onset was 8 years (range: 1-14 years). The typical manifestation of skin lesion with central umbilication was not common (21.4%). All the children had very low CD4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.